Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Causes and Outcomes of Community Acquired Pneumonia (CAP)

This study has been completed.
Information provided by (Responsible Party):
Oxford University Clinical Research Unit, Vietnam Identifier:
First received: April 6, 2011
Last updated: September 29, 2016
Last verified: September 2016

This is a descriptive clinical research aiming:

  • To describe the clinical spectrum and clinical characteristics of community acquired pneumonia (CAP) in patients admitted to hospital
  • To identify the etiology of CAP and the antibiotic sensitivity of the isolated organisms
  • To identify the risk factors that influence the severity of CAP

Community Acquired Pneumonia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Etiology, Clinical Manifestations and Risk Factors for Community-acquired Pneumonia in Patients Admitted to Hospital

Resource links provided by NLM:

Further study details as provided by Oxford University Clinical Research Unit, Vietnam:

Primary Outcome Measures:
  • Proportion of patients who are stable at Day 3, 7 and 14 [ Time Frame: up to 14 days ] [ Designated as safety issue: No ]

    • Criteria for clinical stability

    • Temperature < or = 37.8oC
    • Heart rate < or = 100 beats/min
    • Respiratory rate < or = 24 breaths/min
    • Systolic blood pressure > or = 90 mm Hg
    • Arterial oxygen saturation > or = 90% or pO2 > or = 60 mm Hg on room air
    • Ability to maintain oral intake
    • Normal mental status

Secondary Outcome Measures:
  • Day 14 mortality [ Time Frame: 14 days ] [ Designated as safety issue: No ]
    Proportion of patients who die at Day 14

  • Length of stay (days) [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 2 weeks ] [ Designated as safety issue: No ]
    Length of stay from admission to discharge in days

  • Need for mechanical ventilation [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 2 weeks ] [ Designated as safety issue: No ]
  • Length of ventilation time [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 2 weeks ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA
Sputum Blood Urine Nasal and Throat swab

Enrollment: 300
Study Start Date: February 2011
Study Completion Date: February 2014
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Detailed Description:
In Vietnam, the range and relative contribution of organisms causing CAP remain unclear, largely because diagnostic tools are limited and clinical research uncommon. An improved understanding of the risk factors, etiology and clinical outcomes of CAP in Vietnam would contribute to improved approaches to patient diagnosis and clinical management. This will be achieved by following the clinical and laboratory progress and treatment outcomes of in-patients diagnosed with CAP from admission to discharge. Comparative analyses will be between subgroups including survivor and non-survivor, severe CAP and non-severe CAP, known etiology and unknown etiology, SIRS, sepsis, severe sepsis and shock septic.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
300 patients with community acquired pneumonia who meet the below inclusion/ exclusion criteria will be recruited at two hospitals in Vietnam.

Inclusion Criteria:

  • Patients > or = 18 years of age
  • Patient meets the criteria of pneumonia (below), established within 36h of hospitalization
  • Patient is not hospitalized or residing in a long-term-care facility within 14 days before the onset of symptoms
  • Patient has not been at a referral hospital for >2 days before admission to the study hospital
  • Informed consent to participate in the study is provided

Exclusion Criteria:

  • Severe immunosuppression as judged by the enrolling physician (e.g. HIV, leukemia, lymphoma, chemotherapy for solid tumors, long-term corticosteroid use or other immunosuppressive drugs)
  • Known active tuberculosis or current treatment for tuberculosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01336036

National Hospital of Tropical Diseases
Hanoi, Vietnam
Nguyen Tri Phuong Hospital
Ho Chi Minh, Vietnam
Sponsors and Collaborators
Oxford University Clinical Research Unit, Vietnam
Principal Investigator: Kinh V Nguyen, PhD National Hospital of Tropical Diseases
Principal Investigator: Peter Horby, Dr. Oxford University Clinical Research Unit - Hanoi
Principal Investigator: Rogier van Doorn, MD Oxford University Clinical Research Unit
  More Information

Additional Information:
Responsible Party: Oxford University Clinical Research Unit, Vietnam Identifier: NCT01336036     History of Changes
Other Study ID Numbers: 03HN 
Study First Received: April 6, 2011
Last Updated: September 29, 2016
Health Authority: Vietnam: Ministry of Health

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections processed this record on October 21, 2016